SLS Stock Jumps on New Institutional Disclosures and Clinical Milestones

Sellas Life Sciences (SLS) shares rose to their strongest close in over a week as new institutional disclosures and encouraging clinical timelines caught investor attention.

JPMorgan Chase opened a 100,135-share stake in SLS, valued at $1.48 million as of June 30, while Stifel Financial increased its holdings by nearly 8% to 12,419 shares worth about $183,300, according to Quiver Quantitative.

The Phase 3 Regal trial has recorded 78 of the 80 events required to trigger its final GPS analysis. Meanwhile, Sellas has enrolled 28 of the planned 80 patients in its Phase 2 SLS009 AML trial, with initial data expected in Q4.